Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8412354 | 0.97 | DNM1 (0.36) | DNM1KDM5A | |
| SCHEMBL128205 | 0.97 | DNM1 (0.36) | DNM1KDM5A | |
| SCHEMBL8409800 | 0.97 | DNM1 (0.36) | DNM1KDM5A | |
| SCHEMBL128172 | 0.92 | HRH3 (0.31) | DRD2DRD3HRH3 | |
| SCHEMBL28199223 | 0.89 | HRH3 (0.30) | HRH3 | |
| SCHEMBL128657 | 0.89 | KDM5A (0.38) | DNM1KDM5A | |
| SCHEMBL2045798 | 0.89 | DNM1 (0.43) | DNM1DRD2DRD3KDM5A | |
| SCHEMBL9579283 | 0.87 | KCNH2 (0.40) | DNM1DRD3 | |
| SCHEMBL1405659 | 0.86 | DNM1 (0.48) | DNM1DRD2DRD3KDM5A | |
| SCHEMBL5384597 | 0.86 | DNM1 (0.42) | DNM1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023276967-A1 | OSMOREGULATOR | 国立大学法人九州大学 | 2023-01-05 | — | — | WO | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-7563580-B2 | Nucleic acid adsorbent; methods for adsorbing, removing, dissociating, and recovering nucleic acids using the same; and method for regenerating the same | CHISSO CORPORATION (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-20080227969-A1 | Nucleic acid adsorbent; methods for adsorbing, removing, dissociating, and recovering nucleic acids using the same; and method for regenerating the same | JNC CORPORATION (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7358050-B2 | Nucleic acid adsorbent; methods for adsorbing, removing, dissociating, and recovering nucleic acids using the same; and method for regenerating the same | CHISSO CORPORATION (JP) | 2008-04-15 | — | — | US | disclosed |
| US-5443829-A | For enhancing delivery of drugs across mucous membranes of animals | CAMBRIDGE BIOTECH CORPORATION (US) | 1995-08-22 | — | — | US | disclosed |
| EP-0658111-A1 | METHODS FOR ENHANCING DRUG DELIVERY WITH MODIFIED SAPONINS | CAMBRIDGE BIOTECH CORPORATION (US) | 1995-06-21 | — | — | EP | disclosed |
| EP-0645368-A1 | Process for the purification of tertiary amines from primary and secondary amines | BASF Aktiengesellschaft (DE) | 1995-03-29 | — | — | EP | disclosed |
| WO-1994001118-A1 | METHODS FOR ENHANCING DRUG DELIVERY WITH MODIFIED SAPONINS | CAMBRIDGE BIOTECH CORPORATION (US) | 1994-01-20 | — | — | WO | disclosed |
| US-5273965-A | A reduced and hydrolyzed saponin from a Quillaja saponaria extract | CAMBRIDGE BIOTECH CORPORATION (US) | 1993-12-28 | — | — | US | disclosed |
| US-4351768-A | CARBONLESS, DUPLICATION, INDOLE DYES | STERLING DRUG INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4322352-A | Indolyl phthalide compounds | STERLING DRUG INC. (US) | 1982-03-30 | — | — | US | disclosed |
| US-4307018-A | CHROMOGENS FOR COPYING SYSTEMS | STERLING DRUG INC. (US) | 1981-12-22 | — | — | US | disclosed |
| US-4251446-A | COLOR PRECURSORS | STERLING DRUG INC. (US) | 1981-02-17 | — | — | US | disclosed |
| US-4189171-A | PRESSURE SENSITIVE, THERMAL AND HECTOGRAPHIC SYSTEMS | STERLING DRUG INC. (US) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227969-A1 | Nucleic acid adsorbent; methods for adsorbing, removing, dissociating, and recovering nucleic acids using the same; and method for regenerating the same | DNMT1, NSUN2, DNA2 | DNM1 2166/4885DRD2 4047/4885DRD4 3891/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | DNM1 3297/4885DRD2 169/4885DRD4 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.